A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma

Journal of Immunotherapy

Volumn 19, Issue 5, 1996, Pages 364-374

  Fenton, Robert G ^a   Steis, Ronald G ^a   Madara, Karen ^b   Zea, Arnold H ^c   Ochoa, Augusto C ^d   Janik, John E ^a   Smith, John W ^e   Gause, Barry L ^a   Sharfman, William H ^f   Urba, Walter J ^g   Hanna, Michael G ^h   DeJager, Robert L ^h   Coyne, Mark X ^h   Crouch, Robert D ⁱ   Gray, Pat ^c   Beveridge, Joy ^a   Creekmore, Stephen P ^a   Holmlund, Jon ^a   Curti, Brendan D ^a   Sznol, Mario ^a   Longo, Dan L ⁱ   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b Atlanta Cancer Care   (United States)

^c Frederick Memorial Hospital   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^g PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTE ON AGING   (United States)

ⁱ NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

IL 2; Immunization; Immunotherapy; T cell; Vaccine

Indexed keywords

ANTIGEN; BCG VACCINE; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR DELTA CHAIN; TUMOR CELL VACCINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOCOMPETENCE; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY CARCINOMA; METASTASIS; MUSCLE WEAKNESS; MYOSITIS; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; UREMIA; VOMITING;

EID: 10544224544     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199609000-00006     Document Type: Article

References (28)

1. MacLean GD, Reddesh MA, Bowen-Yacyshyn MB, Poppema S, Longecker BM. Active specific immunotherapy against adenocarcinomas. Cancer Invest 1994;12:46-56.
2. Hellstrom KE, Hellstrom I. Possibilities for active immunotherapy of human cancer. Cancer Invest 1992;10:285-93.
3. Mitchell MS. Attempts to optimize active specific immunotherapy for melanoma. Int Rev Immunol 1991;7:333-47.
4. Boon T. Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
5. Forni G, Giovarelli M, Cavallo F, et al. Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy. J Immunother 1993;14:253-7.
6. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153-64.
7. Key ME, Hanna MG Jr. Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity: synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. J Natl Cancer Inst 1981;67:853-61.
8. Hoover HC Jr, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
9. Harris J, Ryan L, Adams G, Benson A, Haller D. Survival and relapse in adjuvant autologous tumor vaccine therapy for Dukes B and C colon cancer. Proc ASCO 1994;13:294.
10. McCune CS, Schapira DV, Hanshaw EC. Specific immunotherapy for advanced renal carcinoma: evidence for the polyclonality of metastasis. Cancer 1981;47:1984-7.
11. Sahasrabudhe DM, deKernion JB, Pontes JE, et al. Specific im-munotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Response Mod 1986;5:581-94.
12. Berd D, Maguire HC, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8: 1858-67.
13. Berd D, Maguire HC, Mastrangelo MJ. Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 1993;690:147-52.
14. Nathan FE, Mastrangelo MJ. Adjuvant therapy for cutaneous melanoma. Semin Oncol 1995;22:647-61.
15. − mutation. Proc Natl Acad Sci USA 1988;85:2274-78.
16. Kageshita T, Wang Z, Calorini L, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993;53:3349-54.
17. Restifo NP, Kawakami Y, Marincola F, et al. Molecular mechanisms used by tumors to escape immune recognition: immunotherapy and the cell biology of MHC class I. J Immunother 1993: 14:182-90.
18. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992;71:1065-8.
19. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
20. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
21. Weinberg A, Merigan TC. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. J Immunol 1988;140:294-9.
22. Nunberg JH, Doyle MV, York SM, York CJ. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci USA 1989;86:4240-3.
23. Uchiyama A, Hoon DS, Morisaki T. Kaneda Y, Yuzuki DH, Morton DL. Transfection of interleukin 2 gene into human melanoma cells augments cellular immune responses. Cancer Res 1993; 53: 949-52.
24. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
25. Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992:258:1795-8.
26. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing zeta chains in tumor infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-2.
27. Abbas AK, Lichtman AH, Pober JS. Effector mechanisms of T cell-mediated immune reactions. Cellular and molecular immunol-ogy, 2nd ed. Philadelphia: WB Saunders, 1994:262-77.
28. Mitchell MS, Jakowatz J, Harel W, et al. Increased effectiveness of interferon alpha-2b following active specific immunotherapy for melanoma. J Clin Oncol 1994;12:402-11.